All In Biotech

Drug Trial Radar · NCT07425392

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Prior Pneumococcal Vaccination

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 752 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

752

Actual

Start

Feb 9, 2026

Primary completion

Oct 25, 2026

Study completion Oct 25, 2026

Sponsor

Lead sponsor
Vaxcyte, Inc.Industry
Sponsor type
Industry
First posted
Feb 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.

Conditions

  • Pneumococcal Disease

Interventions

  • 31-valent pneumococcal conjugate vaccineBiological

    0.5 mL of VAX-31 will be administered into the deltoid muscle

  • PCV20Biological

    0.5 mL of the 20-valent pneumococcal conjugate vaccine will be administered into the deltoid muscle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serotype-specific OPA geometric mean titers (GMT)Time frame: 1 month after VAX-31 vaccination
  2. Serotype-specific OPA geometric mean fold rise (GMFR) from baselineTime frame: 1 month after VAX-31 vaccination
  3. Percentage of subjects reporting solicited local adverse events (AE) (redness, swelling, and pain at injection site)Time frame: up to 7 days after vaccination
  4. Percentage of subjects reporting solicited systemic AE (fever, headache, fatigue, muscle pain, and joint pain)Time frame: up to 7 days after vaccination
  5. Percentage of subjects reporting unsolicited AETime frame: up to 31 days after vaccination
  6. Percentage of subjects reporting new onset of chronic illness (NOCI), medically attended AE (MAAE), and serious adverse events (SAE)Time frame: up to 6 months after vaccination

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Chinle Center for Indigenous Health

    Chinle, Arizona

  • Avacare (CCT Research)

    Phoenix, Arizona

  • Whiteriver Center for Indigenous Health

    Whiteriver, Arizona

  • Chase Medical Research

    Waterbury, Connecticut

  • CenExel (RCA)

    Hollywood, Florida

  • Eximia (Health Awareness)

    Jupiter, Florida

  • Eximia (Health Awareness)

    Port Saint Lucie, Florida

  • Precision Clinical Research

    Sunrise, Florida

  • The Villages

    The Villages, Florida

  • DelRicht Clinical Research

    Stockbridge, Georgia

  • Velocity Clinical Valparaiso

    Valparaiso, Indiana

  • Johnson County Clin-Trials, LLC

    Lenexa, Kansas

  • DelRicht Clinical Research

    New Orleans, Louisiana

  • Velocity (Meridian Clinical Research)

    Rockville, Maryland

  • DM Clinical Research-Detroit

    Southfield, Michigan

  • AMR

    Kansas City, Missouri

  • DelRicht Research (Command Family Medicine)

    Springfield, Missouri

  • Quality Clinical Research

    Omaha, Nebraska

  • Center of American Indian Health

    Gallup, New Mexico

  • Shiprock Center for Indigenous Health

    Shiprock, New Mexico

  • Rochester Clinical Research, Inc.

    Rochester, New York

  • Headlands (Trial Management Associates)

    Wilmington, North Carolina

  • Tekton Research

    Edmond, Oklahoma

  • DelRicht Research

    Hendersonville, Tennessee

  • Tekton Research

    Austin, Texas

  • REX Clinical Trials

    Beaumont, Texas

  • Flourish Research

    San Antonio, Texas

  • DM Clinical Research

    Sugar Land, Texas

  • Alcanza (Charlottesville Medical Research)

    Charlottesville, Virginia

  • Health Research of Hampton Roads, Inc.

    Newport News, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.